Celcuity 3Q 2026: Revenue $0, EPS ($1.33) — 10-Q Summary
Celcuity reported no revenue in Q3 2026, with a net loss of $73.34M and EPS of ($1.33). Expenses rose due to commercialization efforts. REVTORPYK launched commercially, and the company submitted an sNDA for its use in advanced breast cancer. New data was presented at ESMO Congress, and a prostate cancer study showed promising results.
How this was made
The 30-second read
Why it matters
The disclosed financials indicate heightened cash burn and operational scaling costs, likely prompting a sell‑off.
Market read
Micro‑cap biotech earnings with a loss may depress the stock and affect similar small‑cap biotech sentiment.
What to watch
Potential future revenue from REVTORPYK and pending sNDA could improve outlook.
Background
Celcuity reported its Q3 2026 results via a 10‑Q filing, highlighting zero product revenue and a larger net loss.
Ticker impact
Celcuity filed its 10‑Q showing $0 revenue and a widened net loss of $73.34M for Q3 2026.
downward pressure as investors price in higher expenses and lack of revenue
Earnings miss and increased SG&A indicate operational challenges without offsetting revenue.
Market effects
Biotech small‑cap earnings may weigh on sector sentiment but limited broader impact.
US biotech market sees modest negative bias.
Minimal global effect.
Counterpoint
If the upcoming product launch gains traction, the loss may be temporary.
Key entities
- CompanyCelcuity Inc.
US‑listed biotech company reporting Q3 2026 results.
